Alcami Announces Senior Leadership Appointments

News provided by

May 08, 2020, 07:00 ET

WILMINGTON, N.C., May 8, 2020 /PRNewswire/ -- Alcami, a North Carolina-based contract development and manufacturing organization (CDMO) today announced the appointment of Sally Langa and Kimberly McClintock to their Senior Leadership team. Sally Langa has been appointed to the role of Senior Vice President of Sales and Kimberly McClintock has been appointed to the role of Vice President of Marketing and Client Services.

Sally Langa brings a vast experience in client-facing leadership roles in the contract service industry and a track record of creating technically capable and high-performing sales teams. Before joining Alcami, Sally was the Head of US sales at Nanoform. Prior to this, she held senior leadership roles at Catalent as VP Global Development and Analytical Services, VP of Sales & Marketing at Halo Pharma, and over twenty-five years at Patheon. Sally will be responsible for leading the Business Development teams.

Kimberly McClintock, VP of Marketing and Client Services, returns to Alcami after spending three-years at Mayne Pharma as EVP of Metrics Contract Services and then Portfolio Management. Kim brings over twenty years of industry experience and a successful track record in a variety of R&D and commercial roles while at Banner Life Sciences and Patheon. In addition to leading the Marketing team, Kim will also oversee Project Management, Bids and Proposals, and the company's comprehensive array of laboratory service offerings.

"Sally and Kim bring proven leadership experience to Alcami and have made an immediate contribution to our employees and customers," commented Chief Financial Officer Eric Evans. "We welcome Kim and Sally to the Alcami team."

About Alcami:

Alcami is a contract development, manufacturing, and testing organization headquartered in North Carolina with over 40 years of experience advancing products through every stage of the development lifecycle. Approximately 900 Alcami employees across 6 sites in the United States serve biologics and pharmaceutical companies of all sizes, helping to deliver breakthrough therapies to patients faster. Alcami provides customizable and innovative solutions for API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, clinical and commercial finished dosage form manufacturing (oral solid dose and parenteral), packaging, and stability services. www.alcaminow.com

About Ampersand Capital Partners:

Founded in 1988, Ampersand Capital Partners is a middle-market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Avista Pharma, Brammer Bio, Confluent Medical, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories. Additional information about Ampersand Capital Partners is available at www.ampersandcapital.com.

About Madison Dearborn Partners:

Madison Dearborn Partners, LLC ("MDP") is a leading private equity investment firm based in Chicago. Since MDP's formation in 1992, the firm has raised aggregate capital of over $26 billion and has completed over 145 investments. MDP invests across five dedicated industry verticals, including basic industries; business and government software and services; financial and transaction services; health care; and telecom, media and technology services. For more information, please visit www.mdcp.com.

SOURCE Alcami Corporation